Pharmacy Daily | Sigma posts strong first half results

SIGMA Healthcare has recorded strong sales and profit growth in its financial results for the half year ending 31 Dec 2025, which were released today.

Highlights included a normalised EBIT of $582.9 million, up 18.7% on the previous corresponding period, and revenue of $5.5 billion, up 14.9%.

Sales for Australian Chemist Warehouse stores came in at $5.1 billion, up 17.2%, while international stores recorded a 24.5% increase in sales to $807 million.

The group added 13 Chemist Warehouse-branded stores in Australia, bringing its total to 550.

Meanwhile, early indications suggest the transformations of the Amcal and Discount Drug Stores are progressing well.

The sale of GLP-1 receptor agonists and similar were noted to have contributed to sales uplift, along with the strategic decision to distribute online orders directly from stores.

While stating that Chemist Warehouse "is and always will be a house of brands", the group is expanding its portfolio of owned and exclusive label products, with 400 new lines added in the half year.

International markets have also experienced accelerated growth, and with 12 stores opening in the first half year and another dozen to open in the second half, this is expected to continue.

"The first half performance underscores the strength of our integrated business model and the compelling opportunities ahead," said CEO and managing director Vikesh Ramsunder.

"We are delivering growth across all markets and channels, strengthening our product capability and progressing the integration with discipline."

Ramsunder noted that the first seven weeks of the second half showed continued growth both in Australia and internationally, providing a positive overall outlook for the financial year.

"With solid trading momentum and synergy benefits still ahead of us, Sigma is well positioned to deliver sustained growth and long-term shareholder value," Ramsunder concluded. KB